CRL

Business profile & competitive position

Charles River Laboratories International, Inc. (CRL) operates in the Healthcare sector, specifically the Medical - Diagnostics & Research industry. The company functions as a full-service, non-clinical global drug development partner, supplying research model technologies, discovery and safety assessment services (both GLP and non-GLP), and manufacturing support products and services. Its operations are organized into three reportable segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. In 2025, total revenue was $4.0 billion, with DSA contributing 59.8% of revenue, RMS contributing 21.1%, and Manufacturing Solutions contributing 19.1%.

The company runs more than 120 sites across over 20 countries, giving it a broad geographic footprint in the non-clinical outsourcing market. Yet the current margin profile tempers any qualitative moat argument. CRL's net margin is -6.0% and its return on equity is -7.7%, meaning it is currently not converting revenue into accounting profit, nor is it generating positive returns on shareholders' equity. Those figures do not negate the company's scale or scientific capabilities, but they do show the competitive position is under earnings pressure. The data alone cannot say whether that pressure is temporary or structural.

Financial posture

Charles River currently carries a market capitalization of $13.9 billion and a P/E ratio of -59.6. The negative P/E follows directly from the negative net margin: when earnings are below zero, the price-to-earnings multiple becomes negative rather than a meaningful valuation premium or discount. The ROE figure of -7.7% reinforces that the company is in a loss-making phase on an equity basis. Beta is 1.41, indicating the stock has historically been roughly 41% more volatile than the overall market.

The current snapshot as of the data generation date shows CRL trading at $288.5, with a 50-day exponential moving average of $257.03 and an RSI of 60.1. That price sits approximately 12% above the 50-day EMA and just above neutral RSI territory. The backdrop includes a reported post-earnings advance: one recent headline noted the stock had risen 10.5% since its last earnings report on August 5, 2026.

Strategic priorities & outlook

Charles River's most recent 10-K filing outlines an operational agenda centered on consolidation and integration. Over the next two years, the company expects to close or consolidate approximately 12 additional sites, principally within the DSA and RMS segments. That footprint optimization suggests management is focused on matching physical capacity to current demand rather than expanding capacity aggressively.

The company is also integrating Discovery Services and Safety Assessment into one overarching DSA organization, combining the sales force and leadership approach. The stated objective is to become the scientific partner of choice by delivering a comprehensive, integrated portfolio designed to accelerate biomedical research and therapeutic innovation. At the same time, Charles River is pursuing opportunities to expand its Biologics Testing Solutions service offerings and facilities in the U.S. and Europe.

A concrete strategic move came in January 2026, when the company acquired certain assets of K.F. (Cambodia) Ltd., a provider of non-human primates, to support DSA supply operations and RMS third-party sales. That acquisition links directly to securing research animal supply chains for safety assessment work.

Macro & geopolitical exposure

Because CRL is classified in Healthcare / Medical - Diagnostics & Research, its macro exposures stem from biopharma research spending, regulatory oversight, and the global movement of biological materials. The DSA segment depends on pharmaceutical and biotechnology clients outsourcing non-clinical safety assessment, making demand sensitive to early-stage drug-development budgets and venture-capital availability.

Research model sourcing creates additional exposure to animal welfare regulations, import controls, customs delays, and international supply-chain reliability. With operations spanning more than 20 countries, currency translation is also relevant: a stronger U.S. dollar can reduce the reported value of revenue generated overseas. Trade policy matters because research models, biological samples, and testing materials regularly cross borders. Finally, the broader U.S. healthcare regulatory environment—including FDA inspection practices and evolving non-clinical safety standards—can influence demand for Charles River's outsourced services.

Recent developments

Recent news coverage has clustered around valuation and momentum. On September 4, 2026, zacks.com noted that Charles River had climbed 10.5% since its last earnings report and asked whether the move could continue. A day earlier, on September 1, 2026, zacks.com published a piece asking whether the stock was the right time for portfolios. Defenseworld.net, on August 31, 2026, contrasted Charles River Laboratories with IB Acquisition (NASDAQ:IBAC). None of these headlines offered company-specific operational catalysts; instead they framed the debate around price action and relative valuation after the August earnings result.

Also appearing in the news cluster was an August 27, 2026 fool.com article about Wall Street backing the Clarity Act and the path forward for crypto. That headline is unrelated to Charles River's core business.

Earnings behavior & post-earnings drift

CRL's earnings history stands out for consistency. Over the last eight reported quarters, the company has beaten the consensus estimate every time, for a 100% beat rate, with an average earnings surprise of 9.3%. The average five-day price move following those releases has been 1.24% to the upside, classified as an upward post-earnings drift.

The most recent report, on August 5, 2026, continued the streak: actual EPS was $3.02 against the market's real expectation of $2.74, a 10.2% surprise. The stock rose 1.84% the next session and 9.07% over the following five trading days. The prior quarter, May 7, 2026, produced EPS of $2.06 versus $2.96, a 5.1% surprise, but the reaction was sharply negative: the stock fell 2.23% the next day and 12.42% over the following five sessions. Before that, February 18, 2026, saw $2.39 actual versus $2.33 estimate (2.6% surprise), with a 3.95% one-day gain and 6.05% five-day gain. The November 5, 2025 quarter delivered $2.43 versus $2.32 (4.7% surprise), with next-day and five-day moves of 1.9% and 2.27%, respectively.

That track record carries a lesson for event-driven analysis: a perfect beat rate does not guarantee a positive price reaction in any single quarter. The May 2026 episode shows the market can still punish the stock even when headline EPS exceeds estimates. The next report is scheduled for November 4, 2026 before the open, with the unofficial consensus EPS estimate at $2.96.

For a broader assessment of analyst sentiment, institutional positioning, and the full range of estimates for CRL, readers should consult the complete institutional verdict rather than relying on this earnings-history snapshot alone.